HOME
>
臨床医学：内科
>
小児科学一般
> 小児科臨床ピクシス　22　小児のネフローゼと腎炎

小児科臨床ピクシス　22　小児のネフローゼと腎炎

出版社：	中山書店
著者：	五十嵐隆／総編集
発行日：	2010-11-25
分野：	臨床医学：内科 > 小児科学一般
ISBN：	9784521733098
シリーズ：	小児科臨床ピクシス
電子書籍版：	2010-11-25 （初版第2刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

9,350 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

9,350 円(税込)

購入する

商品紹介

日本の小児腎臓病医療は3歳検尿、学校検尿が早期発見・治療に大きく貢献し、腎炎やネフローゼによる腎不全は減少したといわれています。しかし、先天性よる腎不全、生物製剤の導入、薬剤の適応外使用、移植、医療援助制度など小児腎・ネフローゼを診るために必要な知識や情報に終りはありません。本書は、よりよい治療のために日々奮闘し、患児とその家族とともに現在、臨床の現場で診療にあたる中堅と若手の医師が今、現場で本当に必要な事を指南した1冊です。

目次

小児科臨床ピクシス　22　小児のネフローゼと腎炎

―目次―

1章　総論
2章　ネフローゼ症候群
3章　急性腎炎・慢性腎炎
4章　膠原病の腎病変
5章　遺伝性腎症
6章　尿細管疾患
7章　先天性腎・泌尿器疾患
8章　慢性腎不全
9章　社会的支援・対応
10章　治療薬・治療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章総論

P.11 掲載の参考文献

1) Uemura O, et al. Chronic kidney disease in children. Nippon Rinsho 2008 ; 66 : 1814-20.

2) Matsuo S, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009 ; 53 : 982-92.

3) Heilbron DC, et al. Expressing glomerular filtration rate in children. Pediatr Nephrol 1991 ; 5 : 5-11.

4) Schwartz GJ, et al. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984 ; 104 : 849-54.

5) Schwartz GJ, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976 ; 58 : 259-63.

6) Schwartz GJ, et al. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987 ; 34 : 571-90.

7) Counahan R, et al. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976 ; 51 : 875-8.

8) 上村治ほか. 小児慢性腎臓病の腎機能評価ツールとしてのシスタチンCの問題点. 日本小児科学会雑誌 2009 ; 113 : 335.

9) 早川英樹ほか. 小児の正常血清クレアチニン値 (酵素法) の検討身長との関係. 医学検査 2004 ; 53 : 1285-9.

10) Uemura O, et al. Reference serum creatinine levels determined by an enzymatic method in Japanese children : relationship to body length. Clin Exp Nephrol 2009 ; 13 : 585-8.

P.15 掲載の参考文献

1) 石倉健司, 本田雅敬. 急性腎炎症候群. 東京都立清瀬小児病院編. 実践で役立つ小児外来診療指針. 大阪 : 永井書店 ; 2004. p.362-364.

2) 小島洋子. クレアチニン. 日本公衆衛生協会. 日本人小児の臨床検査基準値. 1997. p.137-140.

3) 田中聡子ほか. 本邦小児の高血圧患者における基礎疾患. 小児高血圧研究会誌 2007 ; 4 : 23-27.

4) Avner ED, et al. editors. Pediatric Nephrology, 6th ed. New York : Springer ; 2009.

5) 五十嵐隆. 小児腎疾患の臨床, 改訂第3版. 東京 : 診断と治療社 ; 2008.

P.19 掲載の参考文献

1) 五十嵐隆. 小児腎疾患の臨床, 改訂第3版. 東京 : 診断と治療社 ; 2008. p.82-4.

2) 坂口弘ほか編著. 新腎生検の病理-腎臓病アトラス. 東京 : 診断と治療社 ; 2003. p.159-82.

3) 日本腎臓学会・腎生検検討委員会. 腎生検ガイドブック-より安全な腎生検を施行するために. 東京 : 東京医学社 ; 2004.

4) 日本腎臓学会. http://www.jsn.or.jp/member/members/guidelines/jinseiken.php

5) 親への説明マニュアル. 腎生検. 小児科診療. 2002 ; 65 : 1834-7.

6) Silva FG, et al. Renal Biopsy Interpretation. New York : Churchill Livingstone ; 1997. p.21-31.

P.23 掲載の参考文献

1) 日本腎臓学会・腎病理診断標準化委員会, 日本腎病理協会編. 腎生検病理アトラス. 東京 : 東京医学社 ; 2010.

2) Weening JJ, et al. The classification of glomerulonephritis in systemic lupus erythematosus reviseited. Kidney int 2004 ; 65 : 521-30.

3) D'Agati VD, et al. Pathologic classification of focal segmental glomerulosclerosis : a working proposal. Am J Kidney Dis 2004 ; 43 : 368-82.

4) Roberts ISD, et al. The Oxford classification of IgA nephropathy : pathology definitions, correlations, and reproducibility. Kidney international ; 2009. p.1-11.

5) Rogers TE, et al. Glomerular diseases associated with nephritic syndrome and/or rapidly progressive glomerulonephritis. In : Zhou XJ et al. editors. Silva's Diagnostic Renal Pathology. Cambridge : Cambridge Univ pr ; 2009. p.178-228.

P.27 掲載の参考文献

1) Bruce A, et al. 中村桂子ほか監訳. 細胞の分子生物学, 第5版. 東京 : ニュートンプレス ; 2010.

2) 特集小児疾患における臨床遺伝学の進歩. 小児科 2009 ; 50 : 803-1232.

3) 松原洋一. 遺伝子診断-研究から臨床応用へ. 小児内科 2008 ; 40 : 1250-4.

4) 野津寛大. 腎疾患の診断における遺伝子解析の有用性. 小児内科 2009 ; 41 : 213-20.

P.31 掲載の参考文献

1) 野津寛大ほか. 腎疾患の診断における遺伝子解析の有用性. 小児内科 2009 ; 40 増刊 : 923-7.

P.36 掲載の参考文献

1) Honda M, et al. The Japanese National Registry data on Pediatric CAPD patients : a ten-year experience. A report of the Study Group of Pediatric PD Conference. Perit Dial Int 1996 ; 16 : 269-75.

2) Hattori S, et al. The 1999 report of the Japanese National Registry Data on Pediatric End-Stage Renal Program. Jpn J Pediatr Nephrol 2001 ; 14 : 165-73.

3) 村上睦美. 腎臓病検診の実施成績と分析. 東京都予防医学協会年報 2005 ; 22-30.

4) 日本学校保健会心臓・腎臓等管理指導小委員会. 腎疾患患児-新・学校生活管理指導のしおり (学校・学校医用). 日本学校保健会 ; 2002.

5) 松山健. 腎臓学校検診はどのようにすべきか. 腎臓 2005 ; 28 : 29-31.

P.39 掲載の参考文献

1) Greenhalgh T, Hurwitz B. Narrative Based Medicine : Dialogue and Discourse in Clinical Practice. London : BMJ Books ; 1998. /斉藤清二ほか訳. ナラティブ・ベイスト・メディスン-臨床における物語りと対話. 東京 : 金剛出版 ; 2001.

P.43 掲載の参考文献

1) Mulrow CD, et al. Systematic reviews : critical links in the great chain of evidence. Ann Intern Med 1997 ; 126 : 389-91.

2) 中山健夫. EBMを用いた診療ガイドライン作成・活用ガイド. 東京 : 金原出版 ; 2004. p.82-5.

3) Gallin JI編, 井村裕夫監. NIH臨床研究の基本と実際. 東京 : 丸善 ; 2004. p.206-9.

4) Emanuel JE, et al. What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis 2004 ; 189 : 930-7.

2章ネフローゼ症候群

P.47 掲載の参考文献

1) Tryggvason K, Pettersson E. Causes and consequences of proteinuria : the kidney filtration barrier and progressive renal failure. J Intern Med 2003 ; 254 : 216-24.

2) Tojo A, Endou H. Intrarenal handLing of proteins in rats using fractional micropuncture technique. Am J Physiol 1992 ; 263 : F601-6.

3) Rheault MN, et al. Mouse model of X-linked Alport syndrome. J Am Soc Nephrol 2004 ; 15 : 1466-74.

4) Jarad G, et al. Proteinuria precedes podocyte abnormalities in Lamb2-/- mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 2006 ; 116 : 2272-9.

5) Morita H, et al. Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol 2005 ; 16 : 1703-10.

6) Smithies O. Why the kidney glomerulus does not clog : a gel permeation/diffusion hypothesis of renal function. Proc Nati Acad Sci U S A 2003 ; 100 : 4108-13.

7) Ohlson M, et al. A gel-membrane model of glomerular charge and size selectivity in series. Am J Physiol Renal Physiol 2001 ; 280 : F396-405.

8) Takahashi S, et al. Charge selective function in childhood glomerular diseases. Pediatr Res 2006 ; 59 : 336-40.

9) Norden AG, et al. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int 2001 ; 60 : 1885-92.

10) Saito H, et al. Reevaluation of glomerular charge selective protein-sieving function. Pediatr Nephrol 2009 ; 24 : 609-12.

P.51 掲載の参考文献

1) Tryggvason K, et al. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006 ; 354 : 1387-401.

2) Faul C, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008 ; 14 : 931-8.

3) Jones N, et al. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature 2006 ; 440 : 818-23.

4) Harita Y, et al. Phosphorylation of nephrin triggers Ca2+ signaling by recruitment and activation of phospholipase C-gamma 1. J Biol Chem 2009 ; 284 : 8951-62.

5) Hara M, et al. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998 ; 18 : 35-41.

6) Reiser J, Mundel P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr Hypertens Rep 2007 ; 9 : 403-8.

P.55 掲載の参考文献

1) Eddy AA, Symons JM. Nephrotic syndrome in children. Lancet 2003 ; 362 : 629-39.

2) 長田道夫ほか. たんぱく尿の成因に関しての最近の知見. 腎臓 2010 ; 32 : 176-83.

3) Bruneau S, Dantal J. New insights into the pathophysiology of idiopathic nephrotic syndrome. Clin Immunol 2009 ; 133 : 13-21.

4) Marszal J, Saleem MA. The bioactivity of plasma factors in focal segmental glomerulosclerosis. Nephron Exp Nephrol 2006 ; 104 : e1-5.

5) Hattori M, et al. Increase of integrin-linked kinase activity in cultured podocytes upon stimulation with plasma from patients with recurrent FSGS. Am J Transplant 2008 ; 8 : 1550-6.

P.61 掲載の参考文献

1) Wu HM, Tang JL, et al. Interventions for preventing infection in nephrotic syndrome. Cochrane Database Syst Rev 2004 ; (2) : CD003964.

2) 田村啓成, 石倉健司ほか. 小児特発性ネフローゼ症候群における細菌性腹膜炎. 日本小児科学会雑誌 2009 ; 113 : 935-8.

3) Agarwal N, Phadke KD, et al. Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2003 ; 18 : 1289-92.

4) Kerlin BA, Blatt NB, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome : a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 2009 ; 155 : 105-10.

5) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会. 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン. 東京 : メディカルフロントインターナショナルリミテッド ; 2004.

P.65 掲載の参考文献

1) Avner ED, et al. editors. Pediatric nephrology, 5th edition. Philadelphia : Lippincott Williams & Wilkins ; 2003.

2) Jalanko H. Congenital nephrotic syndrome. Pediatr Nephrol 2009 ; 24 : 2121-8.

3) Johnstone DB, Holzman LB. Clinical impact of research on the podocyte slit diaphragm. Nat Clin Pract Nephrol 2006 ; 2 : 271-82.

4) 綾邦彦. 先天性・乳児ネフローゼ症候群. 小児内科40巻増刊号, 小児疾患診療のための病態生理 1, 改訂第4版 ; 2008.

P.69 掲載の参考文献

1) Hodson EM, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007 ; 17 : CD001533.

2) Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003 ; 362 : 629-39.

3) Avner ED, et al. editors. Idiopathic nephrotic syndrome in children : clinical aspects. In : Pediatric Nephrology, 6th edition. Berlin, Heidelberg : Springer-Verlag ; 2009. p.684-7.

4) Cattran DC, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int 2007 ; 72 : 1429-47.

5) Ishikura K, et al. Effective and safe treatment with cyclosporine in nephrotic children : a prospective, randomized multicenter trial. Kidney Int 2008 ; 73 : 1167-73

6) 田村啓成ほか. 小児特発性ネフローゼ症候群における細菌性腹膜炎. 日児会雑誌 2009 ; 113 : 935-8.

P.73 掲載の参考文献

1) Hodson EM, et al. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2006 ; 19 : CD003594.

2) Niaudet P, et al. Cyclosporine in the therapy of steroid-resistant idiopathic nephrotic syndrome. Kidney Int Suppl 1997 ; 58 : S85-90.

3) Mendoza SA, et al. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990 ; 4 : 303-7.

4) Hamasaki Y, et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2009 ; 24 : 2177-85.

P.75 掲載の参考文献

1) Harris RC, Ismail N. Extrarenal complications of the nephrotic syndrome. Am J Kidney Dis 1994 ; 23 : 477-97.

2) Rose BD, et al. Mechanism and treatment of edema in nephrotic syndrome. Up to date. 2009.9.30.

3) 厚生労働省医薬食品局血液対策課. アルブミン製剤の適正使用. 血液製剤の使用指針, 改定版. 2005 ; 41-71.

4) Dharmaraj R, et al. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. Pediatr Nephrol 2009 ; 24 : 775-82.

5) Wu HM, et al. Interventions for preventing infection in nephrotic syndrome. The Cochrane collaboration ; 2009. Issue 2. p.1-21.

3章急性腎炎・慢性腎炎

P.80 掲載の参考文献

1) UpToDate. www.uptodate.com. updated July. 23, 2009.

2) Avner ED, et al. editors. Acute Postinfectious Glomerulonephritis. Pediatric Nephrology, 6th edition. Berlin, Heidelberg : Springer-Verlag ; 2009. p.743-55.

P.85 掲載の参考文献

1) Beck LH Jr, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009 ; 361 : 11-21.

2) Ikezumi Y, et al. Activated macrophages down-regulate podocyte nephrin and podocin expression via stress-activated protein kinases. Biochem Biophys Res Commun 2008 ; 376 : 706-11.

3) Ikezumi Y, et al. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 2003 ; 63 : 83-95.

4) Ikezumi Y, et al. The sialoadhesin (CD169) expressing a macrophage subset in human proliferative glomerulonephritis. Nephrol Dial Transplant 2005 ; 20 : 2704-13.

5) Ikezumi Y, et al. Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis. Am J Nephrol 2010 ; 31 : 273-82.

P.89 掲載の参考文献

1) Nakanishi K, Yoshikawa N. Immunoglobulin A nephropathy. In : Avner ED, et al. editors. Pediatric Nephrology, 6th edition. Berlin, Heidelberg : Springer-vergag ; 2009. p.757-81.

2) Yoshikawa N, Nakanishi K. Chronic nephritis in children-with emphasis on IgA nephropathy. In : Hogg RJ, editor. Kidney Disorders in Children and Adolescents. London, New York : Informa Healthcare ; 2006. p.103-15.

3) Coppo R, et al. IgACE : a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007 ; 18 : 1880-8.

4) Nakanishi K, et al. Japanese Pediatric IgA Nephropathy Treatment Study Group. Efficacy and safety of lisinopril for mild childhood IgA nephropathy : a pilot study. Pediatr Nephrol 2009 ; 24 : 845-9.

5) 吉川徳茂ほか. 巣状・微小メサンギウム増殖を示す小児期IgA腎症における柴苓湯治療のプロスペクティブコントロールスタディ. 日腎会誌 1997 ; 39 : 503-6.

P.93 掲載の参考文献

1) Nakanishi K, Yoshikawa N. Immunoglobulin A nephropathy. In : Avner ED, et al. editors. Pediatric Nephrology, 6th edition. Berlin, Heidelberg : Springer-Verlag ; 2009. p.757-81.

2) Yata N, et al. Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol 2008 ; 23 : 905-12*14.

3) Yoshikawa N, et al ; Japanese Pediatric IgA Nephropathy Treatment Study Group. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 1999 ; 10 : 101-9.

4) Yoshikawa N, et al ; Japanese Pediatric IgA Nephropathy Treatment Study Group. Steroid treatment for severe childhood IgA nephropathy : a randomized, controlled trial. Clin J Am Soc Nephrol 2006 ; 1 : 511-7.

5) Yoshikawa N, et al ; Japanese Pediatric IgA Nephropathy Treatment Study Group. Combination therapy with mizoribine for severe childhood IgA nephropathy : a pilot study. Pediatr Nephrol 2008 ; 23 : 757-63.

6) Shima Y, et al. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant (in press) 2010 Jul 2. [Epub ahead of print, doi : 10.1093/ndt/gfq387]

P.97 掲載の参考文献

1) Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol 2010 ; 25 : 1409-18.

2) Tarshish P, et al. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone-a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992 ; 6 : 123-30.

3) Cansick JC, et al. Prognosis, treatment and outcome of childhood mesangiocapillary (membranoproliferative) glomerulonephritis. Nephrol Dial Transplant 2004 ; 19 : 2769-77.

P.101 掲載の参考文献

1) Jefferson JA, Couser WG. Membranous nephropathy in the pediatric popuration. In : Avner ED, et al. editors. Pediatric Nephrology, 6th edition. Berlin, Heidelberg : Springer-Verlag ; 2009. p.799-814.

2) Tsukahara H, et al. Clinical course and outcome of idiopathic membranous nephropathy in Japanese children. Pediatric Nephrol 1993 ; 7 : 387-91.

3) Nangaku M, et al. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005 ; 16 : 1195-204.

4) Farquhar MG, et al. The Heymann nephritis antigenic complex : megalin (gp330) and RAP. J Am Soc Nephrol 1995 ; 6 : 35-47.

5) Neale TJ, et al. Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci USA 1993 ; 90 : 3645-9.

6) Nakatsue T, et al. Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. Kidney Int 2005 ; 67 : 2239-53.

7) Yuan H, et al. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 2002 ; 13 : 946-56.

8) Ehrenreich T, Churg J. Pathology of membranous nephropathy. Pathol Ann 1968 ; 3 : 145-86.

9) Valentini RP, et al. Membranous glomerulonephritis : treatment response and outcome in children. Pediatr Nephrol 2009 ; 24 : 301-8.

10) Lee BH, et al. Idiopathic membranous nephropathy in children. Pediatr Nephrol 2006 ; 21 : 1707-15.

11) Choi MJ, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002 ; 61 : 1098-114

12) Sugiura H, et al. Effect of Single-Dose Rituximab on Primary Glomerular Diseases. Nephrol Clin Pract 2010 ; 117 : c98-c105

13) Chen A, et al. Idiopathic membranous nephropathy in pediatric patients : presentation, response to therapy, and long-term outcome. BMC Nephrol 2007 ; 8 : 11.

P.105 掲載の参考文献

1) Kaku Y, et al. Renal involvement in Henoch-Schonlein purpura : a multivariate analysis of prognostic factors. Kidney Int 1998 ; 53 : 1755-9.

2) Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings : a systematic review. Arch Dis Child 2005 ; 90 : 916-20.

3) Goldstein AR, et al. Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet 1992 ; 339 : 280-2.

4) Zaffanello M, Fanos V. Treatment-based literature of Henoch-Schonlein purpura nephritis in childhood. Pediatr Nephrol 2009 ; 24 : 1901-11.

5) Coppo R, Amore A. Henoch- Schonlein purpura. In : Avner ED, et al. editors. Pediatric Nephrology 6th edition. Berlin, Heidelberg : Springer-Verlag ; 2009. p.1111-26.

P.107 掲載の参考文献

1) Jennette JC, Hipp CG. Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens. Am J Clin Pathol 1985 ; 83 : 415-20.

2) Mii A, et al. Current status and issues of C1q nephropathy. Clin Exp Nephrol 2009 ; 13 : 263-74.

3) Markowitz GS, et al. C1q nephropathy : a variant of focal segmental glomeruloscleosis. Kidney Int 2003 ; 64 : 1232-40.

4) 森野正明ほか. 組織像が異なるC1q腎症の2症例. 日児腎誌 2006 ; 19 : 135-40.

5) 宗秀典ほか. ステロイド抵抗性を示したC1q nephropathyの1歳女児例. 日児腎誌 2007 ; 20 : 208-12.

P.111 掲載の参考文献

1) Bagga A. Crescentic glomerulonephritis. In : Avner ED, et al. editors. Pediatric Nephrology, 6th edition. Berlin, Heidelberg : Springer-Verlag ; 2009. p.815.

2) Hattori M, et al. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J Am Soc Nephrol 2001 ; 12 : 1493-500.

3) 臼井丈一, 山懸邦弘. わが国のRPGNの現状と将来の展望. 日腎会誌 2009 ; 51 : 78-83.

4) 中西浩一, 吉川徳茂. 小児科領域のRPGN. 日腎会誌 2009 ; 51 : 102-6.

5) 急速進行性糸球体腎炎診療指針作成合同委員会 (堺秀人ほか). 急速進行性腎炎症候群の診療指針. 日腎会誌 2002 ; 44 : 55-82. http://www.jsn.or.jp/guideline/

6) Togawa H, et al. Increased chymase-positive mast cells in children with cescentic glomerulonephritis. Pediatr Nephrol 2009 ; 24 : 1071-5.

P.115 掲載の参考文献

1) 本田雅敬. Vero毒素産生大腸菌による溶血性尿毒症症候群の臨床症状と治療. ICUとCCU 1997 ; 21 (臨時増刊) : 285-92.

2) 幡谷浩史, 本田雅敬. 腸管出血性大腸炎による溶血性尿毒症症候群, 脳症の早期診断. 小児内科 1998 ; 30 : 760-3.

3) 幡谷浩史, 本田雅敬. O-157によるHUSの治療. 小児科臨床 1997 ; 50 : 1843-52.

4章膠原病の腎病変

P.119 掲載の参考文献

1) Rahman A, Isenberg DA. Systemic Lupus Erythematosus. N Engl J Med 2008 ; 358 : 929-39.

2) Lee YH, et al. Induction and maintenance therapy for lupus nephritis : a systematic review and meta-analysis. Lupus 2010 ; 19 : 703-10.

3) Zhu B, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis : a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007 ; 22 : 1933-42.

4) Appel GB, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009 ; 20 : 1103-12.

P.123 掲載の参考文献

1) 今井裕一. 腎炎と腎症. 日本腎臓学会誌 2008 ; 50 : 960-73.

2) Hattori M, et al. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J Am Soc Nephrol 2001 : 12 : 1493-500.

3) Russell KA, et al. Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum 2001 : 44 : 463-8.

4) 湯村和子. BVAS (Birmingham vasculitis activity score) とVDI (vasculitis damage index). リウマチ科 2007 ; 37 : 268-78.

5) 急速進行性糸球体腎炎診療指針作成合同委員会. 急速進行性腎炎症候群の診療指針. 日腎会誌 2002 ; 44 : 55-82.

6) Dann EJ, et al. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 2005 : 20 : 2247-9.

7) Bolton WK. Goodpasture's syndrome. Kidney Int 1996 ; 50 : 1753-66.

5章遺伝性腎症

P.125 掲載の参考文献

1) Rogers PW, et al. Familial benign essential hematuria. Arch Intern Med 1973 ; 131 : 257-62.

2) Rangarayyan RM, et al. Segmentation and Analysis of the glomerular basement membrane in renal biopsy samples using active contours : a pilot study. J Digit Imaging 2010 ; 23 : 323-31. http://www.springerlink.com/content/g7u2386x11w8443w/

3) Morita M, et al. Glomerular basement membrane thickness in children. A morphometric study. Pediatr Nephrol 1988 ; 2 : 190-5.

4) Collar JE, et al. Red cell traverse through thin glomerular basement membranes. Kidney Int 2001 ; 59 : 2069-72.

5) Voskarides K, et al.COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 2007 ; 18 : 3004-16.

6章尿細管疾患

P.131 掲載の参考文献

1) Alon US. Tubulointerstitial nephritis. In : Avner ED, et al. editors. Pediatric Nephrology, 6th edition. Berlin, Heidelberg : Springer-Verlag ; 2009. p.1081-98.

2) 武田福治, 佐野元昭. 特発性尿細管間質性腎炎 [急性, 慢性]. 腎臓症候群. 別冊日本臨牀 ; 1997. p.258-61.

P.134 掲載の参考文献

1) Scheel O, et al. Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 2005 ; 436 : 424-7.

2) Gekle M. Renal tubule albumin transport. Annu Rev Physiol 2005 ; 67 : 573-94.

3) Reinhart SC, et al. Characterization of carrier females and affected males with X-linked recessive nephrolithiasis. J Am Soc Nephrol 1995 ; 5 : 1451-61.

4) Sekine T, et al. OCRL1 mutations in patients with Dent disease phenotype in Japan. Pediatr Nephrol 2007 ; 22 : 975-80.

5) Cho HY, et al. Renal manifestations of Dent disease and Lowe syndrome. Pediatr Nephrol 2008 ; 23 : 243-9.

6) Tosetto E, et al. Phenotypic and genetic heterogeneity in Dent's disease -the results of an Italian collaborative study. Nephrol Dial Transplant 2006 ; 21 : 2452-63.

7) Frishberg Y, et al. Dent's disease manifesting as focal glomerulosclerosis : Is it the tip of the iceberg? Pediatr Nephrol 2009 ; 24 : 2369-73.

8) Raja KA, et al. Responsiveness of hypercalciuria to thiazide in Dent's disease. J Am Soc Nephrol 2002 ; 13 : 2938-44.

9) 根東義明. Fanconi症候群. 内山聖ほか編. 専門医のための腎臓病学, 第2版. 東京 : 医学書院 ; 2009. p.568-71.

10) Gahl WA, et al. Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest 1988 ; 81 : 549-60.

11) Watanabe T, et al. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol 2005 ; 20 : 814-7.

7章先天性腎・泌尿器疾患

P.139 掲載の参考文献

1) Nutahara K, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 2005 ; 99 : c18-23.

2) Gattone VH, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003 ; 9 : 1323-6.

3) Ward CJ, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor like protein. Nat Genet 2002 ; 30 : 259-69.

4) 佐藤保則ほか. カロリ病と肝線維症. 肝胆膵 2007 ; 55 : 275-83.

5) Roy S, et al. Autosomal recessive polycystic kidney disease : long-term outcome of neonatal survivors. Pediatr Nephrol 1997 ; 11 : 302-6.

P.144 掲載の参考文献

1) 佐々木尚美ほか. 小児期に末期腎不全に至った先天性異・低形成腎の発見契機と臨床症状. 日本小児科学会雑誌 2007 ; 111 : 1045-51.

2) 米田香織ほか. 多嚢胞性異形成腎 (Multicystic dysplastic kidney : MCDK) の臨床的解析. 日児腎誌 2007 ; 20 : 15-9.

3) Cambio AJ, et al. Non-surgical management of multicystic dysplastic kidney. BJU Int 2008 ; 101 : 804-8.

4) 粟津緑. 腎尿路奇形. 小児内科 2008 ; 40 : 881-6.

5) Hains DS, et al. Management and etiology of the unilateral multicystic dysplastic kidney : a review. Pediatr Nephrol 2009 ; 24 : 233-41.

8章慢性腎不全

P.151 掲載の参考文献

1) Hattori S, et al. The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients. Pediatr Nephrol 2002 ; 17 : 456-61.

2) 服部新三郎ほか. 小児腎不全の疫学調査. 臨牀透析 2005 ; 21 : 1315-22.

3) Warady BA, Chadha V. Chronic kidney disease in children : the global perspective. Pediatr Nephrol 2007 ; 22 : 1999-2009.

4) Karlberg J, et al. Early age-dependent growth impairment in chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. Pediatr Nephrol 1996 ; 10 : 283-7.

5) 亀井宏一ほか. 透析患児における心機能の評価. 日小児腎不全会誌 2003 ; 23 : 142-3.

6) Fadrowski JJ, et al. Hemoglobin decline in children with chronic kidney disease : baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol 2008 ; 3 : 457-62.

P.157 掲載の参考文献

1) McDonald SP, Craig JC ; Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004 : 350 : 2654-62.

2) 本田雅敬. 小児末期腎不全の管理. 日児誌 2004 : 108 : 3-11.

3) Warady BA, et al. Optimal care of the pediatric end-stage renal disease patient on dialysis. Am J Kidney Dis 1999 : 33 : 567-83.

4) 服部新三郎. 小児腎不全の疫学調査. 臨牀透析 2005 ; 21 : 1315-22.

5) 宍戸清一郎ほか. 本邦における小児腎移植の現況と長期成績. 移植 2007 ; 42 : 347-53.

6) 服部元史ほか. 本邦における小児腎移植-原因疾患に関する検討. 移植 2009 ; 44 : 69-78.

7) NAPRTCS (North American Pediatric Renal Trials and Collaborative Studies) 2008 Annual Report. NAPRTCS. http://web.emmes.com/study/ped/index.htm

8) Watson AR, Gartland C : European Paediatric Peritoneal Dialysis Working Group. Guidelines by an Ad Hoc European Committee for Elective Chronic Peritoneal Dialysis in Pediatric Patients. Perit Dial Int 2001 ; 21 : 240-4.

9) White CT, et al. Clinical practice guidelines for pediatric peritoneal dialysis. Pediatr Nephrol 2006 ; 21 : 1059-66.

10) 日本腎臓学会編. エビデンスに基づくCKD診療ガイドライン. 東京 : 東京医学社 ; 2009. エビデンスに基づくCKD診療ガイドライン. 小児CKDの治療. http://www.jsn.or.jp/ckd/pdf/CKD17.pdf

11) 河村毅ほか. 乳児への生体腎移植の経験. 日本小児腎不全学会雑誌 2005 ; 25 : 28-9.

12) 本山治ほか. 低体重児 (6600 g) への生体腎移植の経験. 小児腎不全研究会誌 1989 ; 9 : 216-9.

13) 本田雅敬. 小児における腹膜透析. Pharma Medica 2005 ; 23 Suppl : 67-81.

14) 本田雅敬. 腹膜透析治療の現況-2001. 小児PD研究会雑誌 2001 ; 16 : 44-9.

15) Vats AN, et al. Pretransplant dialysis status and outcome of renal transplantation in North American children : a NAPRTCS Study. North American Pediatric Renal Transplant Cooperative Study. Transplantation 2000 ; 69 : 1414-9.

16) Shishido S, et al. ABO-incompatible living-donor kidney transplantation in children. Transplantation 2001 ; 72 : 1037-42.

17) 宍戸清一郎. 小児の腎移植 Urologic Surgeryシリーズ 10, 腎移植と血管外科. 東京 : メジカルビュー社 ; 2001.

18) 和田尚弘. 成長ホルモン未使用の小児PD患児における長期の成長障害の経過. 小児PD研究会誌 2000 ; 13 : 32-5.

19) 宍戸清一郎. 小児腎移植. 今日の移植 2010 ; 23 : 507-13.

20) 高橋公太. わが国のABO血液型不適合腎移植の統計第12回アンケート調査報告. 今日の移植 2008 ; 21.

9章社会的支援・対応

P.163 掲載の参考文献

1) 服部元史. 小児末期慢性腎不全診療の歩みと現況-第53回日本透析医学会教育講演より. 日本透析医学会雑誌 2009 ; 42 : 137-44.

2) 駒松仁子. 子ども理解を深める. 谷川弘治ほか編. 病気の子どもの心理社会的支援入門-医療保育・病弱教育・医療ソーシャルワーク・心理臨床を学ぶ人に. 京都 : ナカニシヤ出版 ; 2004. p.9-54.

3) 谷川弘治. 心理社会的支援サービスの諸原則と領域. 谷川弘治ほか編. 病気の子どもの心理社会的支援入門-医療保育・病弱教育・医療ソーシャルワーク・心理臨床を学ぶ人に. 京都 : ナカニシヤ出版 ; 2004. p.80-90.

10章治療薬・治療法

P.167 掲載の参考文献

1) 長澤公平. ステロイド治療と骨壊死. 日本医事新報 2002 ; 4099 : 19-25.

2) Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mecahanisms for old drugs. N Engl J Med 2005 ; 353 : 1711-23.

3) 幡谷浩史, 池田昌弘. ネフローゼ症候群. 小児科 2005 ; 46 : 1404-10.

P.171 掲載の参考文献

1) Faul C, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008 ; 14 : 931-8.

2) Cattran DC, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int 2007 ; 72 : 1429-47.

3) Ishikura K, et al. Effective and safe treatment with cyclosporine in nephrotic children : a prospective, randomized multicenter trial. Kidney Int 2008 ; 73 : 1167-73.

4) Hamasaki Y, et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2009 ; 24 : 2177-85.

5) Ishikura K, et al. Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. Nephrol Dial Transplant 2008 ; 23 : 2531-36.

P.175 掲載の参考文献

1) 廣村桂樹. シクロホスファミド. 腎と透析 2009 ; 66 : 950-2.

2) Gipson DS, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009 ; 124 (2) : 747-57.

3) Barratt T, et al. Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet 2 1970 ; 479-82.

4) Hodson EM, et al. Non-corticosteroid treatment for nephrotic syndrome in children (Review). Cochrane Database Syst Rev 2008 Jan 23 ; (1) : CD002290.

5) Austin HA 3rd, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986 ; 314 : 614-9.

6) Austin HA 3rd, Balow JE. Treatment of lupus nephritis. Seminars in Nephrology. 2000 ; 20 : 265-76.

7) 伊藤秀一. シクロフォスファミドパルス療法. 小児内科 2008 ; 40 : 1951-4.

8) 林典子ほか. シクロフォスファミドパルス療法の対象疾患の考え方. 小児内科 2004 ; 36 : 1457-61.

9) 谷澤隆邦. シクロフォスファミド-小児. 腎と透析臨時増刊号 2005 : 619-22.

10) Latta K, et al. A meta-analysis of cytotoxic treatment for frequently relapsing nephritic syndrome in children. Pediatr Nephrol 2001 ; 16 : 271-82.

P.179 掲載の参考文献

1) Villarroel MC, et al. Mycophenolate mofetil : an update. Drugs Today 2009 ; 45 : 521-32.

2) Falcini F, et al. Mycophenolate mofetil for the treatment juvenile onset SLE : a multicenter study. Lupus 2009 ; 18 : 139-43.

3) Fujinaga S, et al. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. Pediatr Nephrol 2008 ; 23 : 1877-82.

4) Dorresteijn EM, et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 2008 ; 23 : 2013-20.

5) Fujinaga S, et al. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine : extended experience in a single center. Clin Nephrol 2009 ; 72 : 268-73.

P.182 掲載の参考文献

1) Ohtomo Y, et al. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol 2005 : 20 : 1744-9.

2) Tanaka Y, et al. Combination therapy with steroids and mizoribine in juvenile SLE : a randomized controlled trial. Pediatr Nephrol 2010 : 25 ; 877-82.

3) Tanaka H, et al. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children : an openlabel pilot study with five newly diagnosed patients. Clin Rheumatol 2008 ; 27 : 85-9.

P.185 掲載の参考文献

1) Benz K, et al. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004 ; 19 : 794-7.

2) Nozu K, et al. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005 ; 20 : 1660-3.

3) Kamei K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009 ; 24 : 1321-8.

4) Fujinaga S, et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010 ; 25 : 539-44.

5) Bagga A, et al. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007 ; 356 : 2751-2.

6) Nakayama M, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008 ; 23 : 481-5.

7) Kaito H, et al. Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of rituximab, steroids and cyclosporine. Pediatr Nephrol 2010 ; 25 : 957-9.

8) Kamei K, et al. Severe respiratory adverse events associated with rituximab infusion. Pediatr Nephrol 2010 ; 25 : 1193.

P.191 掲載の参考文献

1) Hattori M, et al. Plasmapheresis as the sole therapy for rapidLy progressive Henoch-Schonlein purpura nephritis in children. Am J Kidney Dis 1999 ; 33 : 427-33.

2) 服部元史. 難治性ネフローゼ症候群に対するアフェレシス療法. 小児科 2007 ; 48 : 169-176.

3) Szczepiorkowski ZM, et al. Guidelines on the use of therapeutic apheresis in clinical practice : evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007 ; 22 : 106-75.

4) 相馬泉ほか. 小児に対するアフェレシス-小児へのアフェレシス. 日本アフェレシス学会編. 新版アフェレシスマニュアル-難治疾患の治療革命. 東京 : 秀潤社 ; 2004. p.173-80.

5) 近本裕子ほか. 抗凝固薬. 伊藤克己監. 小児急性血液浄化療法マニュアル. 東京 : 医学図書出版 ; 2002. p.32-8.

6) 相馬泉ほか. 小児に対するアフェレシス-小児へのアフェレシス. 日本アフェレシス学会編. 新版アフェレシスマニュアル-難治疾患の治療革命. 東京 : 秀潤社 ; 2004. p.173-180.

7) 江口圭, ほか編. 吸着療法. CE 技術シリーズ血液浄化療法. 東京 : 南江堂 ; 2004. p.231-64.

8) Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 2010 ; 25 : 25-31.

9) Muso E, et al. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 2007 ; 67 : 341-4.

10) Hattori M, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroidresistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003 ; 42 : 1121-30.

P.194 掲載の参考文献

1) Takamatsu M, et al. Glomerular angiotensinogen protein is enhanced in pediatric IgA nephropathy. Pediatr Nephrol 2008 ; 23 : 1257-67.

2) Urushihara M, et al. Urinary angiotensinogen accurately reflects intrarenal Rennin-Angiotensin system activity. Am J Nephrol 2010 ; 31 : 318-25.

3) Lande MB, Flynn JT. Treatment of hypertension in children and adLescents. Pediatr Nephrol 2009 ; 24 : 1939-49.

4) Coppo R, et al. IgACE : a placebo-xcontrolled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007 ; 18 : 1880-8.

5) Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease : pathophysiology and indications. Kidney Int 2005 ; 67 : 799-812.

P.199 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会. 高血圧治療ガイドライン 2009. 日本高血圧学会 ; 2009. p.83-6.

2) National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adlescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004 ; 114 : 555-76.

3) Lurbe E, et al. Management of high blood pressure in children and adolescents : recommendations of the European Society of Hypertension. J Hypertens 2009 ; 27 : 1719-42.

P.203 掲載の参考文献

1) Kondo Y, et al. Phylogenetic, ontogenetic, and pathological aspects of the urine-concentrating mechanism. Clin Exp Nephrol 2006 ; 10 : 165-74.

2) Gamba G, Friedman PA. Thick ascending limb : the Na (+) : K (+) : 2Cl (-) co-transporter, NKCC2, and the calcium-sensing receptor, CaSR. Pflugers Arch 2009 ; 458 : 61-76.

3) Woudenberg-Vrenken TE, et al. The role of transient receptor potential channels in kidney disease. Nat Rev Nephrol 2009 ; 5 : 441-9.

4) Srivastava T, Schwaderer A. Diagnosis and management of hypercalciuria in children. Curr Opin Pediatr 2009 ; 21 : 214-9.

P.208 掲載の参考文献

1) 和田尚弘, 永渕弘之. 急性血液浄化で子供たち救うために～小児急性血液浄化WG の取組みより～. 「小児における治療標準化の背景と取り組み」, 「小児における治療標準化に向けた実践」. 第19回日本急性血液浄化学会において2008年9月20日発表.

2) Symons JM, et al. Demographic characteristics of pediatric continuous renal replacement therapy : a report of the prospective pediatric continuous renal replacement therapy registry. Clin J Am Soc Nephrol. 2007 ; 2 : 732-8.

3) Strazdins V, et al. ; European Pediatric Peritoneal Sialysis Working Group. Renal replacement therapy for acute renal failure in children : European guidelines. Pediatr Nephrol. 2004 ; 19 : 199-207.

4) Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure. Pediatr Nephrol. 2002 ; 17 : 61-9.

書評

書評を投稿する

最近チェックした商品履歴

Loading...